Envista price target raised to $21 from $19 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Envista (NVST) to $21 from $19 and keeps an Equal Weight rating on the shares. The firm’s U.S. dental survey suggests softer practice volume across Q1, but the Specialty segment, including clear aligner and implant, demand improved slightly, the analyst tells investors.